<DOC>
	<DOCNO>NCT01887886</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled study evaluate safety efficacy onartuzumab combination erlotinib patient previously untreated , unresectable stage IIIB IV non-small cell lung cancer identify carry activate EGFR mutation MET-positive . Patients randomize receive either onartuzumab 15 mg/kg intravenously every 3 week combination erlotinib 150 mg orally daily placebo combination erlotinib . Anticipated time study treatment disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>A Study Onartuzumab Combination With Erlotinib Patients With MET-Positive Stage IIIB IV Non-Small Cell Lung Cancer Carrying Activating Epidermal Growth Factor Receptor ( EGFR ) Mutation</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Histologically confirm , unresectable Stage IIIB IV nonsmall cell lung cancer ( NSCLC ) No prior treatment unresectable Stage IIIB IV NSCLC Measurable radiographic evidence disease accord RECIST v1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Prior exposure agent target either Hepatocyte Growth Factor ( HGF ) MET pathway Exposure investigational market agent act EGFR inhibition Pleural effusion , pericardial fluid , ascites require drainage every week frequently Brain metastasis spinal cord compression definitively treat surgery and/or radiation , previously diagnose treated central nervous system ( CNS ) metastases spinal cord compression without evidence clinically stable disease &gt; /=4 day . Note : Patients treat CNS metastasis asymptomatic stable dose corticosteroid &gt; /= 14 day prior randomization eligible . History another malignancy previous 5 year , unless cure surgery alone continuously diseasefree Radiographically evident interstitial lung disease , concurrent infection , history condition Inadequate hematologic , biochemical , organ function Pregnant lactating woman Life expectancy &lt; 12 week Receipt investigational drug within 28 day prior initiation study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>